| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Non-Small-Cell Lung | 25 | 2022 | 1125 | 5.460 |
Why?
|
| Lung Neoplasms | 33 | 2022 | 2362 | 5.000 |
Why?
|
| Chemoradiotherapy | 19 | 2022 | 305 | 3.960 |
Why?
|
| Radiosurgery | 14 | 2022 | 286 | 3.620 |
Why?
|
| Carcinoma, Squamous Cell | 14 | 2021 | 1096 | 3.070 |
Why?
|
| Oropharyngeal Neoplasms | 7 | 2022 | 132 | 2.210 |
Why?
|
| Neoadjuvant Therapy | 12 | 2017 | 374 | 2.200 |
Why?
|
| Neoplasm Staging | 36 | 2022 | 2000 | 2.190 |
Why?
|
| Hodgkin Disease | 6 | 2016 | 181 | 2.190 |
Why?
|
| Adenocarcinoma | 9 | 2020 | 1183 | 2.040 |
Why?
|
| Radiotherapy, Intensity-Modulated | 8 | 2019 | 173 | 1.760 |
Why?
|
| Databases, Factual | 15 | 2022 | 870 | 1.740 |
Why?
|
| Brain Neoplasms | 9 | 2019 | 782 | 1.360 |
Why?
|
| Carcinoma, Large Cell | 4 | 2021 | 39 | 1.360 |
Why?
|
| Chemoradiotherapy, Adjuvant | 6 | 2020 | 36 | 1.340 |
Why?
|
| Middle Aged | 62 | 2024 | 26195 | 1.310 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 8 | 2019 | 185 | 1.300 |
Why?
|
| Aged | 53 | 2024 | 19282 | 1.250 |
Why?
|
| Male | 72 | 2024 | 42741 | 1.210 |
Why?
|
| Papillomavirus Infections | 5 | 2022 | 264 | 1.210 |
Why?
|
| Chemotherapy, Adjuvant | 5 | 2019 | 476 | 1.170 |
Why?
|
| Female | 72 | 2024 | 46656 | 1.140 |
Why?
|
| Radiotherapy Dosage | 13 | 2019 | 468 | 1.070 |
Why?
|
| Aged, 80 and over | 28 | 2021 | 6786 | 1.050 |
Why?
|
| Small Cell Lung Carcinoma | 3 | 2022 | 112 | 1.040 |
Why?
|
| Glioblastoma | 4 | 2017 | 266 | 1.040 |
Why?
|
| SEER Program | 16 | 2020 | 205 | 1.000 |
Why?
|
| United States | 31 | 2022 | 7118 | 0.990 |
Why?
|
| Early Detection of Cancer | 4 | 2021 | 423 | 0.960 |
Why?
|
| Survival Analysis | 14 | 2019 | 1496 | 0.960 |
Why?
|
| Humans | 94 | 2024 | 90071 | 0.950 |
Why?
|
| Kaplan-Meier Estimate | 13 | 2020 | 853 | 0.940 |
Why?
|
| Registries | 5 | 2017 | 809 | 0.930 |
Why?
|
| Neoplasm, Residual | 3 | 2016 | 182 | 0.930 |
Why?
|
| Survival Rate | 16 | 2019 | 1901 | 0.930 |
Why?
|
| Proportional Hazards Models | 14 | 2020 | 847 | 0.920 |
Why?
|
| Combined Modality Therapy | 14 | 2019 | 1706 | 0.920 |
Why?
|
| Adult | 47 | 2024 | 26855 | 0.920 |
Why?
|
| Palliative Care | 3 | 2018 | 264 | 0.910 |
Why?
|
| Young Adult | 26 | 2024 | 6424 | 0.880 |
Why?
|
| Follow-Up Studies | 18 | 2024 | 3689 | 0.850 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2024 | 1350 | 0.820 |
Why?
|
| Esophageal Neoplasms | 3 | 2016 | 331 | 0.810 |
Why?
|
| Healthcare Disparities | 5 | 2021 | 432 | 0.740 |
Why?
|
| Neoplasms, Second Primary | 2 | 2015 | 261 | 0.700 |
Why?
|
| Extremities | 2 | 2013 | 174 | 0.680 |
Why?
|
| Nasopharyngeal Neoplasms | 2 | 2017 | 47 | 0.680 |
Why?
|
| Radiotherapy, Conformal | 3 | 2017 | 82 | 0.680 |
Why?
|
| Lymph Nodes | 4 | 2020 | 551 | 0.670 |
Why?
|
| Sarcoma | 2 | 2013 | 220 | 0.660 |
Why?
|
| Retrospective Studies | 26 | 2024 | 9259 | 0.650 |
Why?
|
| Adolescent | 19 | 2024 | 9363 | 0.650 |
Why?
|
| Multivariate Analysis | 9 | 2017 | 983 | 0.630 |
Why?
|
| Prognosis | 14 | 2022 | 3800 | 0.630 |
Why?
|
| Treatment Outcome | 19 | 2022 | 8313 | 0.620 |
Why?
|
| Cohort Studies | 13 | 2020 | 2891 | 0.610 |
Why?
|
| Health Services Accessibility | 2 | 2021 | 438 | 0.610 |
Why?
|
| Radiotherapy, Adjuvant | 9 | 2020 | 291 | 0.610 |
Why?
|
| Transplantation Conditioning | 6 | 2024 | 374 | 0.600 |
Why?
|
| Stomach Neoplasms | 3 | 2017 | 287 | 0.590 |
Why?
|
| Mass Screening | 2 | 2021 | 649 | 0.580 |
Why?
|
| Hospitals, Low-Volume | 1 | 2017 | 19 | 0.580 |
Why?
|
| Carcinoma | 5 | 2022 | 437 | 0.580 |
Why?
|
| Tongue Neoplasms | 1 | 2017 | 52 | 0.570 |
Why?
|
| Hospitals, High-Volume | 1 | 2017 | 38 | 0.560 |
Why?
|
| Mouth Neoplasms | 2 | 2020 | 199 | 0.530 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2021 | 2675 | 0.520 |
Why?
|
| Esophagectomy | 3 | 2016 | 91 | 0.500 |
Why?
|
| Thoracic Neoplasms | 1 | 2015 | 66 | 0.490 |
Why?
|
| Practice Patterns, Physicians' | 2 | 2020 | 608 | 0.490 |
Why?
|
| Insurance, Health | 5 | 2016 | 164 | 0.480 |
Why?
|
| Induction Chemotherapy | 1 | 2016 | 152 | 0.480 |
Why?
|
| Propensity Score | 8 | 2020 | 151 | 0.480 |
Why?
|
| Mortality | 2 | 2016 | 149 | 0.470 |
Why?
|
| Insurance Coverage | 4 | 2017 | 127 | 0.460 |
Why?
|
| Tumor Burden | 6 | 2020 | 311 | 0.440 |
Why?
|
| Preoperative Care | 2 | 2017 | 396 | 0.440 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 5 | 2018 | 2503 | 0.440 |
Why?
|
| Immunotherapy | 1 | 2019 | 694 | 0.420 |
Why?
|
| Central Nervous System | 1 | 2014 | 153 | 0.420 |
Why?
|
| Organs at Risk | 5 | 2019 | 40 | 0.410 |
Why?
|
| Pneumonectomy | 1 | 2015 | 210 | 0.410 |
Why?
|
| Radiation Injuries | 1 | 2014 | 161 | 0.410 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2015 | 953 | 0.380 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 293 | 0.380 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 4 | 2024 | 892 | 0.380 |
Why?
|
| Ependymoma | 1 | 2011 | 17 | 0.380 |
Why?
|
| Disease-Free Survival | 5 | 2020 | 1170 | 0.370 |
Why?
|
| Breast Neoplasms | 6 | 2015 | 3021 | 0.350 |
Why?
|
| Socioeconomic Factors | 3 | 2017 | 595 | 0.340 |
Why?
|
| Logistic Models | 4 | 2020 | 1215 | 0.330 |
Why?
|
| Lymphatic Metastasis | 5 | 2020 | 497 | 0.330 |
Why?
|
| Brachytherapy | 3 | 2015 | 120 | 0.330 |
Why?
|
| Papillomaviridae | 4 | 2022 | 156 | 0.320 |
Why?
|
| Cytoreduction Surgical Procedures | 2 | 2020 | 79 | 0.320 |
Why?
|
| Radiation Oncology | 4 | 2018 | 122 | 0.310 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2009 | 129 | 0.310 |
Why?
|
| Gallbladder Neoplasms | 1 | 2008 | 23 | 0.310 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2008 | 24 | 0.300 |
Why?
|
| Lymph Node Excision | 3 | 2020 | 221 | 0.300 |
Why?
|
| Prostatic Neoplasms | 5 | 2020 | 1746 | 0.300 |
Why?
|
| Clinical Clerkship | 3 | 2014 | 117 | 0.290 |
Why?
|
| Head and Neck Neoplasms | 3 | 2022 | 1059 | 0.290 |
Why?
|
| Dacarbazine | 2 | 2017 | 101 | 0.260 |
Why?
|
| Salivary Gland Neoplasms | 2 | 2021 | 80 | 0.260 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2018 | 65 | 0.260 |
Why?
|
| Myeloablative Agonists | 2 | 2024 | 36 | 0.260 |
Why?
|
| Busulfan | 2 | 2024 | 41 | 0.260 |
Why?
|
| Comorbidity | 3 | 2020 | 956 | 0.250 |
Why?
|
| Whole-Body Irradiation | 4 | 2024 | 67 | 0.250 |
Why?
|
| Regression Analysis | 3 | 2017 | 591 | 0.240 |
Why?
|
| Neoplasms, Radiation-Induced | 1 | 2005 | 109 | 0.240 |
Why?
|
| Anemia, Sickle Cell | 2 | 2018 | 144 | 0.230 |
Why?
|
| Child, Preschool | 4 | 2015 | 3781 | 0.230 |
Why?
|
| Patient Selection | 2 | 2020 | 682 | 0.230 |
Why?
|
| Osteosarcoma | 1 | 2005 | 161 | 0.230 |
Why?
|
| Cisplatin | 2 | 2016 | 598 | 0.230 |
Why?
|
| Child | 5 | 2015 | 7257 | 0.220 |
Why?
|
| Vidarabine | 1 | 2024 | 144 | 0.220 |
Why?
|
| Prevalence | 3 | 2020 | 1250 | 0.220 |
Why?
|
| Meningioma | 1 | 2024 | 62 | 0.220 |
Why?
|
| Meningeal Neoplasms | 1 | 2024 | 66 | 0.220 |
Why?
|
| Academic Medical Centers | 2 | 2016 | 385 | 0.220 |
Why?
|
| Radiotherapy | 3 | 2016 | 332 | 0.210 |
Why?
|
| Otorhinolaryngologic Surgical Procedures | 2 | 2020 | 17 | 0.210 |
Why?
|
| Postoperative Care | 2 | 2017 | 233 | 0.210 |
Why?
|
| Neoplasm Grading | 5 | 2020 | 375 | 0.210 |
Why?
|
| Practice Guidelines as Topic | 3 | 2021 | 1056 | 0.210 |
Why?
|
| Analysis of Variance | 3 | 2017 | 899 | 0.210 |
Why?
|
| Bone Neoplasms | 2 | 2021 | 321 | 0.210 |
Why?
|
| Career Choice | 2 | 2014 | 148 | 0.200 |
Why?
|
| Intracranial Arteriovenous Malformations | 1 | 2022 | 110 | 0.200 |
Why?
|
| Transplantation, Homologous | 1 | 2024 | 995 | 0.190 |
Why?
|
| Mastectomy | 3 | 2015 | 246 | 0.190 |
Why?
|
| Neoplasm Invasiveness | 3 | 2017 | 568 | 0.190 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2021 | 34 | 0.190 |
Why?
|
| Odontogenic Tumors | 1 | 2020 | 12 | 0.180 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2021 | 43 | 0.180 |
Why?
|
| Neoplasms | 4 | 2017 | 3065 | 0.170 |
Why?
|
| Time-to-Treatment | 1 | 2021 | 124 | 0.170 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2022 | 275 | 0.170 |
Why?
|
| Curriculum | 2 | 2014 | 572 | 0.160 |
Why?
|
| Antineoplastic Agents, Alkylating | 2 | 2017 | 135 | 0.160 |
Why?
|
| Risk Factors | 4 | 2020 | 5574 | 0.160 |
Why?
|
| Chemotherapy, Cancer, Regional Perfusion | 1 | 2018 | 18 | 0.150 |
Why?
|
| Transplantation, Haploidentical | 1 | 2018 | 28 | 0.150 |
Why?
|
| Glossectomy | 1 | 2017 | 4 | 0.150 |
Why?
|
| Reward | 1 | 2020 | 193 | 0.150 |
Why?
|
| Risk Assessment | 3 | 2024 | 2329 | 0.140 |
Why?
|
| Hyperthermia, Induced | 1 | 2018 | 73 | 0.140 |
Why?
|
| Oral Surgical Procedures | 1 | 2017 | 19 | 0.140 |
Why?
|
| Minority Groups | 1 | 2018 | 147 | 0.140 |
Why?
|
| Thymoma | 1 | 2017 | 30 | 0.140 |
Why?
|
| Endosonography | 1 | 2017 | 99 | 0.140 |
Why?
|
| Guideline Adherence | 2 | 2015 | 234 | 0.140 |
Why?
|
| Functional Laterality | 1 | 2017 | 199 | 0.140 |
Why?
|
| Thymus Neoplasms | 1 | 2017 | 43 | 0.140 |
Why?
|
| Peritoneal Neoplasms | 1 | 2018 | 181 | 0.140 |
Why?
|
| Organ Transplantation | 1 | 2020 | 285 | 0.130 |
Why?
|
| Bronchi | 1 | 2017 | 230 | 0.130 |
Why?
|
| Cancer Care Facilities | 1 | 2016 | 30 | 0.130 |
Why?
|
| Margins of Excision | 1 | 2016 | 42 | 0.130 |
Why?
|
| Prostate | 1 | 2020 | 408 | 0.130 |
Why?
|
| Time Factors | 2 | 2017 | 5364 | 0.130 |
Why?
|
| Private Sector | 1 | 2015 | 19 | 0.130 |
Why?
|
| Taxoids | 1 | 2016 | 124 | 0.130 |
Why?
|
| Carboplatin | 1 | 2016 | 311 | 0.130 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2019 | 3480 | 0.130 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 98 | 0.120 |
Why?
|
| Head | 1 | 2016 | 136 | 0.120 |
Why?
|
| Social Class | 1 | 2016 | 136 | 0.120 |
Why?
|
| Relative Biological Effectiveness | 1 | 2015 | 14 | 0.120 |
Why?
|
| Immunosuppressive Agents | 1 | 2020 | 980 | 0.120 |
Why?
|
| Odds Ratio | 1 | 2017 | 682 | 0.120 |
Why?
|
| Epidemiologic Methods | 1 | 2015 | 60 | 0.120 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2015 | 160 | 0.120 |
Why?
|
| Mesothelioma | 1 | 2018 | 323 | 0.120 |
Why?
|
| Confidence Intervals | 2 | 2015 | 221 | 0.120 |
Why?
|
| Dose-Response Relationship, Radiation | 1 | 2015 | 190 | 0.120 |
Why?
|
| Population Surveillance | 1 | 2016 | 216 | 0.120 |
Why?
|
| Disease Management | 1 | 2017 | 328 | 0.120 |
Why?
|
| Needs Assessment | 2 | 2014 | 161 | 0.120 |
Why?
|
| Community Health Services | 1 | 2015 | 81 | 0.120 |
Why?
|
| Unrelated Donors | 1 | 2014 | 45 | 0.120 |
Why?
|
| Fluorouracil | 1 | 2016 | 548 | 0.120 |
Why?
|
| Program Evaluation | 2 | 2014 | 311 | 0.120 |
Why?
|
| Graft Survival | 1 | 2018 | 909 | 0.110 |
Why?
|
| Students, Medical | 3 | 2014 | 423 | 0.110 |
Why?
|
| Surveys and Questionnaires | 1 | 2021 | 2658 | 0.110 |
Why?
|
| Necrosis | 1 | 2014 | 210 | 0.110 |
Why?
|
| Multiple Myeloma | 1 | 2017 | 334 | 0.110 |
Why?
|
| Phantoms, Imaging | 1 | 2016 | 463 | 0.110 |
Why?
|
| Sex Factors | 2 | 2021 | 1075 | 0.110 |
Why?
|
| Bevacizumab | 1 | 2014 | 267 | 0.100 |
Why?
|
| Endometrial Neoplasms | 1 | 2015 | 208 | 0.100 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2015 | 297 | 0.100 |
Why?
|
| Length of Stay | 1 | 2015 | 753 | 0.090 |
Why?
|
| Clinical Competence | 2 | 2014 | 796 | 0.090 |
Why?
|
| Patient Readmission | 1 | 2015 | 355 | 0.090 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2011 | 170 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2014 | 344 | 0.090 |
Why?
|
| Predictive Value of Tests | 1 | 2015 | 1735 | 0.090 |
Why?
|
| Lymphatic Irradiation | 1 | 2010 | 7 | 0.090 |
Why?
|
| Thoracic Wall | 1 | 2010 | 25 | 0.090 |
Why?
|
| Postoperative Complications | 1 | 2020 | 2323 | 0.080 |
Why?
|
| Remission Induction | 1 | 2011 | 741 | 0.080 |
Why?
|
| Gastrectomy | 2 | 2017 | 71 | 0.070 |
Why?
|
| Quality of Life | 1 | 2015 | 1684 | 0.070 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2008 | 163 | 0.070 |
Why?
|
| Retinoblastoma | 1 | 2005 | 28 | 0.060 |
Why?
|
| Rhabdomyosarcoma | 1 | 2005 | 43 | 0.060 |
Why?
|
| Sarcoma, Ewing | 1 | 2005 | 44 | 0.060 |
Why?
|
| Biopsy | 1 | 2008 | 1188 | 0.060 |
Why?
|
| Allografts | 2 | 2015 | 185 | 0.060 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 1604 | 0.060 |
Why?
|
| Age Factors | 2 | 2020 | 1879 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2024 | 443 | 0.050 |
Why?
|
| Medicaid | 2 | 2015 | 242 | 0.050 |
Why?
|
| Cetuximab | 1 | 2022 | 115 | 0.050 |
Why?
|
| Mastectomy, Segmental | 2 | 2012 | 101 | 0.050 |
Why?
|
| Eligibility Determination | 1 | 2021 | 36 | 0.050 |
Why?
|
| Medical History Taking | 1 | 2021 | 83 | 0.050 |
Why?
|
| Hypopharyngeal Neoplasms | 1 | 2020 | 15 | 0.050 |
Why?
|
| Cerebrovascular Circulation | 1 | 2022 | 232 | 0.050 |
Why?
|
| Cigarette Smoking | 1 | 2021 | 36 | 0.050 |
Why?
|
| Chicago | 2 | 2016 | 1434 | 0.040 |
Why?
|
| Laryngeal Neoplasms | 1 | 2020 | 89 | 0.040 |
Why?
|
| Infant, Newborn | 1 | 2005 | 2500 | 0.040 |
Why?
|
| Lung | 2 | 2016 | 1304 | 0.040 |
Why?
|
| Infant | 1 | 2005 | 3197 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 282 | 0.040 |
Why?
|
| Cranial Irradiation | 1 | 2018 | 40 | 0.040 |
Why?
|
| Machine Learning | 1 | 2020 | 270 | 0.040 |
Why?
|
| Body Mass Index | 1 | 2021 | 776 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2017 | 4333 | 0.040 |
Why?
|
| Retreatment | 1 | 2017 | 107 | 0.040 |
Why?
|
| Melphalan | 1 | 2017 | 98 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2017 | 263 | 0.030 |
Why?
|
| Medicare | 1 | 2020 | 427 | 0.030 |
Why?
|
| Transplantation, Autologous | 1 | 2017 | 348 | 0.030 |
Why?
|
| Smoking | 1 | 2020 | 625 | 0.030 |
Why?
|
| Consensus | 1 | 2018 | 369 | 0.030 |
Why?
|
| Workflow | 1 | 2016 | 81 | 0.030 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2016 | 145 | 0.030 |
Why?
|
| Alemtuzumab | 1 | 2015 | 88 | 0.030 |
Why?
|
| Esophagus | 1 | 2016 | 107 | 0.030 |
Why?
|
| Androgen Antagonists | 1 | 2016 | 138 | 0.030 |
Why?
|
| Medically Uninsured | 1 | 2015 | 64 | 0.030 |
Why?
|
| Professional Practice | 1 | 2015 | 46 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2015 | 67 | 0.030 |
Why?
|
| Recurrence | 1 | 2017 | 1150 | 0.030 |
Why?
|
| Actuarial Analysis | 1 | 2014 | 66 | 0.030 |
Why?
|
| Spinal Cord | 1 | 2016 | 255 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2018 | 842 | 0.030 |
Why?
|
| Boston | 1 | 2014 | 37 | 0.030 |
Why?
|
| Consumer Behavior | 1 | 2014 | 31 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2017 | 606 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 2019 | 0.030 |
Why?
|
| Poverty | 1 | 2015 | 183 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 2014 | 118 | 0.030 |
Why?
|
| Self Concept | 1 | 2014 | 135 | 0.030 |
Why?
|
| Program Development | 1 | 2014 | 127 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2019 | 1253 | 0.030 |
Why?
|
| Marital Status | 1 | 2012 | 42 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 1065 | 0.030 |
Why?
|
| Heart | 1 | 2016 | 578 | 0.030 |
Why?
|
| Data Collection | 1 | 2014 | 377 | 0.030 |
Why?
|
| Health Expenditures | 1 | 2013 | 90 | 0.030 |
Why?
|
| Matched-Pair Analysis | 1 | 2012 | 40 | 0.020 |
Why?
|
| Receptors, Progesterone | 1 | 2012 | 175 | 0.020 |
Why?
|
| Internet | 1 | 2014 | 323 | 0.020 |
Why?
|
| Societies, Medical | 1 | 2015 | 584 | 0.020 |
Why?
|
| Algorithms | 1 | 2019 | 1912 | 0.020 |
Why?
|
| Receptors, Estrogen | 1 | 2012 | 394 | 0.020 |
Why?
|
| Robotic Surgical Procedures | 1 | 2015 | 320 | 0.020 |
Why?
|
| Positron-Emission Tomography | 1 | 2009 | 339 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2017 | 2328 | 0.020 |
Why?
|